- €50.59bn
- €45.99bn
- $4.15bn
Netherlands' Argenx Q3 sales jump on strong VYVGART demand
Brief: Argenx Q3 Net Income USD 506 Million
Brief: Argenx Says Phase 3 ALKIVIA Study Met Its Primary Endpoint
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Live Markets: STOXX near 4-month low, Paris down 12% from August record
Argenx heads for worst day in nearly 3 yrs after ending drug study
Brief: Argenx Discontinues Phase 3 Unity Study Of Efgartigimod SC In Sjögren's Disease
Live Markets: Before the bell: Europe slips as bond market jitters persist
Brief: Argenx Announces Positive Topline Results From Phase 2 Study Of Fb102 In Celiac Disease
Europe Research Roundup: 2G Energy, Repsol, Wavestone
Brief: Argenx Completes Acquisition Of Forte Biosciences, Inc.
Europe Research Roundup: Hemnet, Polypeptide Group, UMG
European shares edge lower as luxury stocks weigh; US-Iran tensions linger
Argenx drug Vyvgart meets goal in autoimmune myositis study (updated)
Live Markets: Europe's time to shine?
Live Markets: Tech, miners lift STOXX
Argenx soars after drug efgartigimod met main goal in myositis trial
Live Markets: Europe before the bell: Stocks set for gain as Fed rate hike bets recede
Brief: Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint